Status:
COMPLETED
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Lead Sponsor:
Allergan
Conditions:
Ocular Hypertension
Glaucoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects w...
Eligibility Criteria
Inclusion
- Ocular hypertension or primary open-angle glaucoma
- Females of non-childbearing potential
- Subject requires IOP-lowering therapy in both eyes
- IOP ≥ 22 mm Hg and ≤ 34 mm Hg
- Has a visual acuity score of 20/100 or better in each eye
Exclusion
- Uncontrolled systemic disease
- Active ocular disease
- Alteration of existing chronic systemic medications
- Known allergy or sensitivity to the study medications
- Ophthalmic corticosteroids
- Visual field loss which in the opinion of the investigator is functionally significant
- History of ocular laser, intraocular surgery, or refractive surgery
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT00809848
Start Date
February 1 2009
End Date
May 1 2009
Last Update
October 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Artesia, California, United States